Tyler Van Buren
Stock Analyst at TD Cowen
(1.64)
# 3,059
Out of 4,827 analysts
57
Total ratings
39.13%
Success rate
-5.53%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | n/a | $24.13 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $14.02 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $20.25 | +270.37% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $13.13 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $9.75 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $24.38 | +146.10% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $2.18 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $10.52 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $547.67 | +119.11% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $21.02 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $19.27 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $98.16 | -13.41% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $36.14 | -16.99% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.14 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.86 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $56.26 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $37.81 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.46 | - | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $20.44 | +46.77% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $34.85 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.03 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $29.79 | +134.98% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.26 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.81 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.07 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.71 | +2,823.98% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $4.87 | +17,867.15% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $1.24 | +3,125.81% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $9.64 | +314.94% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $9.90 | +203.03% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.36 | +16,515.90% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.46 | +3,324.66% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.12 | +2,578.57% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $3.12 | +6,310.26% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.31 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.07 | - | 1 | Aug 4, 2017 |
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $24.13
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $14.02
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $20.25
Upside: +270.37%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $13.13
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $9.75
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $24.38
Upside: +146.10%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $2.18
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $10.52
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $547.67
Upside: +119.11%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $21.02
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $19.27
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $98.16
Upside: -13.41%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $36.14
Upside: -16.99%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.14
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $12.86
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $56.26
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $37.81
Upside: -
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.46
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $20.44
Upside: +46.77%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $34.85
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.03
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $29.79
Upside: +134.98%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.26
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.81
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.07
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.71
Upside: +2,823.98%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $4.87
Upside: +17,867.15%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $1.24
Upside: +3,125.81%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $9.64
Upside: +314.94%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $9.90
Upside: +203.03%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.36
Upside: +16,515.90%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.46
Upside: +3,324.66%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $1.12
Upside: +2,578.57%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $3.12
Upside: +6,310.26%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $6.31
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $18.07
Upside: -